Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4 Puritas >98.0% (HPLC) Lenvatinib Mesylate intermedia Factory

Description:

Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus

CAS: 205448-66-4

Puritas: >98.0% (HPLC)

Aspectus: Off-White ad Yellow solidus pulveris

Medium de Lenvatinib Mesylate CAS 857890-39-2

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus
Synonyma Lenvatinib immunditia 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Acidum Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acidum Methyl Ester;Lenvaint-D
CAS Number 205448-66-4
CATTUS Number RF-PI1970
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C12H10ClNO3
M. Pondus 251.67
Ferveret 377.4±37.0℃
Density 1.320±0.06 g/cm3
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Off-White ad Yellow solidus pulveris
1 H NMR Spectrum Congruunt cum Structure
Puritas / Analysis Methodus >98.0% (HPLC)
Damnum in Siccatio <1.00%
Totalis immunditias <2.00%
Test Standard Enterprise Standard
Consuetudinem Intermedia/Immunditia de Mesylate Lenvatinib (CAS: 857890-39-2)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

1

FAQ:

Applicatio:

Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus (CAS: 205448-66-4) medius est Mesylate Lenvatinib (CAS: 857890-39-2).Lenvatinib est medicamentum thyreoidum ab Eisai Corporatione Iaponiae (Codex: E7080) inhibitoris multi-receptoris tyrosini kinasi oralis pertinens et kinasum activitatem endothelialem factorem receptorum R1 (FLT1) inhibere potest; VEG-FR2 (KDR), R3 (FLT4).Lenvatinib etiam impedire potest implicationem aliorum RTKs in angiogenesi pathologica, tumore augmento, et progressu cancri, exceptis functionibus normalibus cellularum inclusis fibroblast aucti (FGF) receptores FGFR1, II, III, IV;factor augmentationis receptae (PDGFR [alpha]), KIT, RET.[Indicationes]: Lenvatinib apta est curatione aegrorum cancri thyroideae localis recursu vel metastasi speciei, progressionis generis et iodi-refractionis radioactivi speciei differentiatae.

Epistulam tuam hic scribe et mitte nobis